@article{88fbbc14-121c-46c5-9d19-9daa8538ff04,
abstract = {{Among the recommendations to prevent heart disease is the maintenance of
normal blood cholesterol levels, through the consumption of a
cardioprotective diet, and if necessary, the use of therapeutics such as
statins. Alterations in the gut microbiota have previously been
associated with the development of obesity, insulin resistance and
increased risk of developing cardiovascular disease (CVD). Probiotics
have since emerged as a potential therapeutic strategy, aimed at
reversing the alterations to the gut microbiome. Indeed, we had
previously found that ingestion of Limosilactobacillus mucosae
DPC 6426 had significantly lowered both blood cholesterol and
triglyceride levels in a pre-clinical apoE mouse model, as well as
modulating the gut microbiota, suggesting strain-specific
cardiometabolic potential. To investigate the translational relevance of
these findings in humans, we conducted a randomised, double-blind,
placebo-controlled clinical trial which assessed the effects of daily
administration of the strain at a dose of 3.8 × 109 CFU/per
day, in mildly hypercholesterolaemic adults, on blood lipid profiles and
the gut microbiota composition. Results demonstrated, despite
successful gastrointestinal transit and recovery of Lactobacillus spp., that Limosilactobacillus mucosae
DPC 6426 was not superior to placebo in modifying blood lipid
concentrations or the gut microbiota composition in healthy, mildly
hypercholesterolaemic adults. Such findings highlight the complexity of
translating probiotic-associated metabolic benefits from preclinical
apoE mouse models to healthy human participants. Further investigations
are warranted to ascertain whether the probiotic dose administered in
this study was insufficient to translate from the pre-clinical apoE
mouse model in such a human cohort.}},
author = {{O'Donovan, Aoife N. and Fouhy, Fiona and Grimaud, Ghjuvan and London, Lis E. E. and Doolan, Andrea and Anesi, Andrea and Mattivi, Fulvio and Ross, R. Paul and Caplice, Noel and Stanton, Catherine}},
issn = {{2045-2322}},
language = {{eng}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{Daily administration of Limosilactobacillus mucosae DPC 6426 had negligible effects on blood lipids in mildly hypercholesterolaemic adults}},
url = {{http://dx.doi.org/10.1038/s41598-026-66210-z}},
doi = {{10.1038/s41598-026-66210-z}},
year = {{2026}},
}